Citius Pharmaceuticals Inc
NASDAQ:CTXR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (4.4), the stock would be worth $0.78 (13% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.9 | $0.69 |
0%
|
| 3-Year Average | 4.4 | $0.78 |
+13%
|
| 5-Year Average | 4.4 | $0.78 |
+13%
|
| Industry Average | 2.7 | $0.47 |
-32%
|
| Country Average | 2.4 | $0.43 |
-38%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$19.2m
|
/ |
Jan 2026
$3.9m
|
= |
|
|
$19.2m
|
/ |
Sep 2026
$65.1m
|
= |
|
|
$19.2m
|
/ |
Sep 2027
$161.2m
|
= |
|
|
$19.2m
|
/ |
Sep 2028
$242.2m
|
= |
|
|
$19.2m
|
/ |
Sep 2029
$212.7m
|
= |
|
|
$19.2m
|
/ |
Sep 2030
$225.8m
|
= |
|
|
$19.2m
|
/ |
Sep 2031
$248.3m
|
= |
|
|
$19.2m
|
/ |
Sep 2032
$262.5m
|
= |
|
|
$19.2m
|
/ |
Sep 2033
$277.1m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Citius Pharmaceuticals Inc
NASDAQ:CTXR
|
15.5m USD | 3.9 | -0.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 12.6 | 39.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 5.6 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 4.8 | 27.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 4.8 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 4.2 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 3.8 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 2.4 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 2.4 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Citius Pharmaceuticals Inc
Glance View
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 15 full-time employees. The company went IPO on 2017-08-03. The firm develops and commercializes critical care products with a focus on anti-infective products in adjunct cancer care, prescription products and mesenchymal stem cell therapy. The company has five products: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. Halo-Lido is a corticosteroid-lidocaine topical formulation, which is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. NoveCite is a mesenchymal stem cell therapy for the treatment of ARDS. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.
